Trading a DNTH straddle lets you take a pure volatility position on Dianthus Therapeutics Inc without committing to a direction. Dianthus Therapeutics Inc's straddle involves buying (or selling) a call and a put at the same strike and expiration, profiting when the stock moves more (or less) than the combined premium implies. Use our scanner to evaluate DNTH straddle pricing in real time and find the moments when expected moves are mispriced.
A long straddle on DNTH profits from large moves in either direction and is a classic play into binary events like earnings, product announcements, or macro releases. A short straddle profits when Dianthus Therapeutics Inc stays range-bound and implied volatility contracts. The breakeven points are simple: strike plus total premium on the upside, strike minus total premium on the downside. Comparing the DNTH straddle price to historical realized moves helps you judge whether the market is overpaying or underpaying for volatility.
Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.
Earnings, product cycles, macro prints — any time volatility itself is the trade, the DNTH straddle is the cleanest expression of that view. Our scanner prices every DNTH straddle against historical realized moves, flags expirations where the market is overpaying or underpaying for vol, and ranks setups by breakeven width and IV rank. Whether you're long a DNTH straddle into a catalyst or short a DNTH straddle to harvest decay, the options straddle setups that matter are all in one place.
